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Abstract
The incidence of implantable arterial post-related bloodstream infections (IAP-RBSI) among 
patients with unresectable hepatic malignancies is not well defined. We reviewed the 9-year 
incidence of IAP-RBSI in patients with hepatic malignancies, at a tertiary care center in Japan. 
The incidence was 1.9 infections per 10,000 catheter days.
Hepatic malignancies including primary (i.e., hepatocellular carcinoma; HCC) and 
metastatic tumors cause substantial mortality. Although intra-hepatic infusion of 
chemotherapeutic agents via an implanted arterial port has been used for treating 
unresectable HCC or hepatic metastases,1–3 the incidence of implantable arterial port-related 
bloodstream infections (IAP-RBSI) has not been previously examined. We reviewed the 
incidence of IAP-RBSI in patients with hepatic malignancies.
Methods
A retrospective cohort study was conducted from January 2003 through December 2011 at 
Teine Keijinkai Medical Center, a 551-bed, tertiary care center in Sapporo, Japan. Patients 
with hepatic malignancies, who had an implantable arterial port placed for intra-arterial 
infusion were eligible. Patients were excluded if they received an implantable arterial port 
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without receiving intra-arterial infusion at the study institution, or died before receiving 
intra-arterial infusion.
The catheter was inserted through the femoral artery and the tip of catheter was positioned in 
the proper hepatic artery under fluoroscopic guidance. The proximal end of catheter was 
then connected to the injection port (Cell Site®, Toray Medical Co., Tokyo, Japan), which 
was implanted subcutaneously in the thigh. Interventional radiologists adhered to maximal 
barrier precautions during the procedure. All patients received one dose of prophylactic 
antibiotic (cefazolin or cefmetazole) before the procedure.
Chemotherapeutic agents were administered via the implantable arterial ports and treatment 
cycles were repeated every 1 to 4 weeks, depending on patient’s underlying malignancy. 
Intra-arterial infusion of chemotherapy was performed either in the hospital or at an 
outpatient clinic. Implantable arterial ports were flushed with heparin after each infusion and 
every two weeks.
The Center for Disease Control and Prevention-National Healthcare Safety Network 
(NHSN) definitions for the catheter-related bloodstream infection was adapted to define 
IAP-RBSI4; patient had clinical evidence of infection and at least one positive blood culture 
with organisms not related to an infection at another site. All blood cultures were drawn 
from peripheral vein, but not from implantable arterial ports. If central venous catheters 
were present at the time of the bloodstream infection, then this was not regarded as an IAP-
RBSI, given the possibility of venous catheter-related bloodstream infection.
The incidence for IAP-RBSI was calculated as the number of cases per 10,000 catheter-
days, per chemotherapy session (i.e., the number of administration of chemotherapeutic 
agents), and per catheter placement. Catheter-days were defined as the number of days 
between implantable arterial port placement and either the date of port removal, date of 
death, date of last follow up, or the study end date.5 This study was approved by the Teine 
Keijinkai Medical Center Institutional Review Board.
Results
During a 9-year study period, 103 patients received implantable arterial ports. Six patients 
(5.8%) received infusion at different institutions, and two (1.9%) died before receiving an 
infusion, leaving 95 patients for analysis (Table 1). Five patients underwent a second 
implantable arterial port placement after the first port was removed because of 
complications; two had IAP-RBSI, three developed non-infectious complications. Therefore, 
100 implantable arterial ports were placed (37,147 catheter-days; 2,622 chemotherapy 
sessions)
The median number of device-days for 100 catheters in 95 patients was 266 (range 13–
1786). Twelve patients had positive blood cultures in the cohort. One patient had a central 
venous catheter in place and four had secondary bacteremia, leaving seven patients (7.4%) 
with IAP-RBSI (Table 2). The overall incidence of IAP-RBSI was 1.9 infections per 10,000 
catheter-days (alternatively, 0.3 infections per 100 chemotherapy sessions or 7.0% of 
catheters placed). The incidence of IAP-RBSI was higher in the latter half of the study 
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period. (0.4 versus 6.3 infections per 10,000 catheter-days; incidence ratio, 17.3; 95% 
confidence interval, 3.4–88.6). The median time to IAP-RBSI was 74 days (range 13–633). 
Three (42.9%) patients did not have their catheter removed; one patient died within 11 days 
of diagnosis, one died 42 days after diagnosis, and the other died from recurrent bacteremia 
due to the same organism 119 days after diagnosis.
Eleven patients developed other infections after implantable arterial port placement. These 
included an arterial port pocket infection (n=1), bloodstream infection with a concomitant 
central venous catheter (n=1), empyema (n=1) and liver abscess/biloma (n=8).
Discussion
Very few studies have investigated the incidence of IAP-RBSI. A previous study reported 3 
infections of the port chamber among 41 patients during 260 treatment courses, but details 
of the infections were not noted.6 As the incidence of hepatic malignancies increases in the 
United States,7, 8 intra-arterial infusion of chemotherapy becomes a more common treatment 
option.1–3
We found that IAP-RBSI occurred relatively infrequently and the incidence density was 
similar to that of implantable venous port-related bloodstream infections.9 In our study, we 
determined IAP-RBSI incidence using three different denominators since a consensus to 
define the denominator for implantable ports was not completely established. Even though 
the NHSN definition states that ports are a permanent catheter and “device-days” should be 
used for denominator,10 the frequency with which these catheters are accessed may be 
highly variable, depending on the patient’s chemotherapy course. This may lead to different 
risks for infection between patients. This challenge has led to using various definitions of 
catheter-days to assess venous port-related bloodstream infection in previous studies.5, 9
It remains unclear why the incidence of IAP-RBSI was higher in the latter half of the study 
period. There were differences in patient characteristics between the two periods, including 
hypertension and HCC, which were more common in the latter half of the study (data not 
shown). These changes might influence the observed difference in the incidence of IAP-
RBSI.
The three patients who had attempted catheter salvage had unfavorable outcomes. Current 
guideline recommends the removal of implantable catheter for bloodstream infection, 
particularly due to Staphylococcus aureus and Gram-negative bacilli.11
In our study, we did not count as an IAP-RBSI in patients who developed liver abscess or 
biloma with bacteremia, as this have been a result of secondary infection of the hepatic 
tumor after chemotherapy. This, however, may have potentially led to an underestimation of 
IAP-RBSI incidence.
The current study demonstrated the incidence and microbiology of IAP-RBSI. 
Establishment of clear definition for a denominator to calculate incidence density for port 
catheters is warranted to assess port-related bloodstream infection.
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Table1
Demographic characteristics of 95 patients with an implantable arterial port placement for primary or 
metastatic hepatic malignancies.
Variable n (%)
Age, year, median (range) 62 (41–81)
Male gender 71 (75)
Type of hepatic malignancy
 Hepatocellular carcinoma 64 (67)
 Metastatic liver tumora 31 (33)
Viral hepatitis
 None 46 (48)
 Hepatitis B 22 (23)
 Hepatitis C 26 (27)
 Both hepatitis B and C 1 (1)
Child-Pugh classification at the time of an IAP placement
 Child-Pugh A 61 (64)
 Child-Pugh B 31 (33)
 Child-Pugh C 3 (3)
Diabetes mellitus 23 (24)
Alcohol use 35 (37)
Body mass index ≥ 25 kg/m2 25 (26)
NOTE. IAP; implantable arterial port.
a
Metastatic liver tumor included; colorectal cancer (n=18), cholangiocarcinoma (n=3), pancreatic cancer (n=2), breast cancer (n=1), and other 
cancer (n=7).
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